Hormone
Arch-backed HC Bioscience closes doors after seeing early data for tRNA asset
Vision, hydrocortisone, Bioscience
AbbVie Enters Obesity Market with $2.3 Billion Gubra Deal for Amylin Analog
AbbVie, Gubra, Obesity treatment, GUB014295 (GUBamy), Amylin analog, Weight loss drug, Pharmaceutical licensing deal
Ascletis’ Oral GLP-1 Drug Shows Promising Early Results in Obesity Treatment, Rivaling Roche’s Candidate
Ascletis Pharma, obesity treatment, oral GLP-1 receptor agonist, ASC30, weight loss, clinical trials, Roche, CT-996, pharmaceutical competition
Dual Hormone Therapies Normalize Sleep Patterns in ALS Mouse Models
Amyotrophic lateral sclerosis (ALS), sleep disturbances, orexin antagonist, melanin-concentrating hormone (MCH), suvorexant, sleep architecture, mouse models
Novo Nordisk Seeks FDA Restriction on Victoza Compounding Amid Ongoing GLP-1 Supply Issues
Novo Nordisk, FDA, Victoza, liraglutide, compounding, GLP-1, supply issues, pharmaceutical regulation
FDA Approves First Generic Version of Victoza (Liraglutide) for Type 2 Diabetes Treatment
FDA approval, generic Victoza, liraglutide, GLP-1 receptor agonist, Type 2 diabetes treatment, affordable medication options
FDA Issues Complete Response Letter for Zealand Pharma’s Glepaglutide in Short Bowel Syndrome Treatment
Zealand Pharma, Glepaglutide, GLP-2 analog, Short Bowel Syndrome (SBS), FDA rejection, Complete Response Letter
Sanofi Invests €1 Billion in Beijing to Enhance Insulin Production Capacity
Sanofi, insulin production, Beijing, investment, pharmaceutical industry
GUBamy, a Weekly Amylin Agonist, Shows Promising Weight Loss and Tolerability in Phase 1 Trial
Amylin agonist, Obesity treatment, Weight loss, Phase 1 trial, GUBamy, Long-acting amylin agonist
FDA Approves Roche’s Itovebi, a PI3K Inhibitor for Advanced Breast Cancer Treatment
Roche, Itovebi, PI3K inhibitor, breast cancer, FDA approval, PIK3CA mutation, hormone receptor-positive, HER2-negative